Trial to delay type 1 diabetes: teplizumab vs. ATG
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study compares two medicines (teplizumab and anti-thymocyte globulin) to see if they can delay the onset of type 1 diabetes in people who are at high risk but don't have symptoms yet. If you have certain diabetes-related antibodies in your blood, this trial might help keep full-blown diabetes away for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child are between 4 and 34 years old.
- You have two or more diabetes-related antibodies in your blood (tested in a single sample).
- Your blood sugar tests show early signs of diabetes (like higher than normal blood sugar levels) within the last 100 days.
- You are in overall good health, without serious infections, immune problems, or other major illnesses.
- You haven't been treated with teplizumab or anti-thymocyte globulin before.
- If you're of childbearing age, you must use birth control during the trial.
- You can live within an hour of the infusion site and have quick access to emergency services.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial is testing a new approach to slow or stop the loss of insulin-making cells in people who were recently diagnosed with type 1 diabetes. It uses a medicine called teplizumab to adjust the immune system, and the goal is to help you keep making your own insulin for as long as possible.
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
This trial tests an experimental drug called teplizumab to see if it can slow down or stop type 1 diabetes from getting worse. It is for Japanese people aged 1 to 34 who have stage 2 type 1 diabetes (blood sugar is slightly abnormal but not yet full diabetes).
This study follows children who are at genetic risk for type 1 diabetes or have early immune signs (autoantibodies) but do not yet need insulin. It provides extra checkups and information to catch the disease early and help families understand their child's risk.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This study tests a low dose of a drug that calms the immune system, followed by either another immune drug or a blood pressure medicine, to see if they can help preserve the body's ability to make insulin in people recently diagnosed with type 1 diabetes. It may help keep your own insulin production going longer.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.